Remove Article Remove Genetics and mental health Remove Sleep and mental health
article thumbnail

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Health care professionals should monitor the child’s growth and development and provide necessary interventions to mitigate weight loss.”

article thumbnail

Eyes, Ears, and Emotion: Techniques to Tackle Diagnosing Bipolar Disorder

Psychiatric Times

Emerging research on RNA biomarkers, AI applications, and genetic mutations shows promise for developing new diagnostic tools for bipolar disorder. However, new research focuses in on RNA biomarkers, RNA editing, artificial intelligence applications, genetic mutations in thyroid pathways, and ceramide-based metabolite profiling.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Psychiatric Pipeline in Review: Quarter 2, 2025

Psychiatric Times

Learn more in this exclusive article. Together, they will aim to bring innovative mental health treatments to patients in need. Participants include 30 young adults diagnosed with BPD and 20 young adults with no mental health diagnosis, who are observed using EEG and behavioral assessments to gather objective data.

article thumbnail

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

1 The newly announced CNPV pathway was introduced by FDA Commissioner Marty Makary, MD, MPH, on June 17, 2025, and is intended to expedite reviews for medications that address US public health priorities. The CNPV program, introduced by FDA Commissioner Marty Makary, aims to reduce review times to 1-2 months for eligible applications.

article thumbnail

Prodromal Symptoms of Schizophrenia: Understanding and Addressing Challenges

Psychiatric Times

Prodromal symptoms encompass mood changes such as anxiety, depression , mood swings, sleep issues, irritability, anger, and potential suicidal thoughts. Studies in Australia and the United States followed individuals with subthreshold psychotic symptoms and functional decline, along with a genetic risk for schizophrenia, over time.

article thumbnail

Accutane and Mental Health: Converging Physical and Emotional Well-being

Lightwork

Your skin health and mental well-being are closely connected. At LightWork Therapy and Recovery , we understand the complex connection between physical treatments and emotional health. In this article, we will delve into the intricate link between Accutane and mental health.

article thumbnail

Is Ondansetron Safe for Women With Mental Health Conditions?

Lightwork

Navigating medication safety during pregnancy can feel overwhelming, especially for women managing mental health conditions. For women with mental health conditions, the decision to use ondansetron requires careful consideration.